Mustang Bio, Inc. Working Capital

Working Capital of MBIO for past 10 years: annual, quarterly and twelve month trailing (TTM) including Working Capital growth rates and interactive chart. Working capital, also known as net working capital (NWC), is the difference between a company’s current assets, such as cash, accounts receivable (customers’ unpaid bills) and inventories of raw materials and finished goods, and its current liabilities, such as accounts payable. Net operating working capital is a measure of a company's liquidity and refers to the difference between operating current assets and operating current liabilities. In many cases these calculations are the same and are derived from company cash plus accounts receivable plus inventories, less accounts payable and less accrued expenses. Working capital is a measure of a company's liquidity, operational efficiency and its short-term financial health. If a company has substantial positive working capital, then it should have the potential to invest and grow. If a company's current assets do not exceed its current liabilities, then it may have trouble growing or paying back creditors, or even go bankrupt.

Highlights and Quick Summary

  • Working Capital for the quarter ending June 29, 2021 was $125 Million (a 0.48% increase compared to previous quarter)
  • Year-over-year quarterly Working Capital increased by 83.79%
  • Annual Working Capital for 2020 was $90 Million (a 62.81% increase from previous year)
  • Annual Working Capital for 2019 was $55.3 Million (a 87.38% increase from previous year)
  • Annual Working Capital for 2018 was $29.5 Million (a -48.9% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Working Capital of Mustang Bio, Inc.

Most recent Working Capitalof MBIO including historical data for past 10 years.

Interactive Chart of Working Capital of Mustang Bio, Inc.

Mustang Bio, Inc. Working Capital for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $124.98 $124.38
2020 $90.02 $68.0 $71.52 $47.67 $90.02
2019 $55.29 $68.07 $77.05 $34.24 $55.29
2018 $29.51 $37.77 $44.44 $50.3 $29.51
2017 $57.75 $64.95 $69.07 $74.21 $57.75
2016 $24.28 $6.25 $24.28
2015 $-4.13

Business Profile of Mustang Bio, Inc.

Sector: Healthcare
Industry: Biotechnology
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.